



RECEIVED

JAN 28 2003

1632

PTO/SB/21 (08-00)

Approval for use through 10/31/2002. OMB 0651-0031

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	<b>Application Number</b>	09/750,456	
	<b>Filing Date</b>	Dec 28, 2000	
	<b>First Named Inventor</b>	Friedrich, Glenn	
	<b>Group Art Unit</b>	1632	
	<b>Examiner Name</b>	Anne-Marie Falk	
<b>Total Number of Pages in This Submission</b>	6	<b>Attorney Docket Number</b>	LEX-0286-USA

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	- Return Postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	- Response to Restriction and Election Requirement with Exhibits A and B
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	<b>Remarks</b>	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Lexicon Genetics Incorporated Lance K. Ishimoto Reg. No. 41,866
Signature	 24231 PATENT TRADEMARK OFFICE
Date	January 17, 2003

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Arlington, VA 22202 on this date: January 17, 2003			
Typed or printed name	Michelle Klein		
Signature		Date	January 17, 2003



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

---

Applicant(s):	Friedrich <i>et al.</i>	Group Art Unit: 1632
Application No.:	09/750,456	Examiner: Anne Marie Falk
Filed:	12/28/00	Attorney Docket No.:
Title: Novel Mutated Mammalian Cells and Animals		LEX-0286-USA

---

**AMENDMENT AND RESPONSE TO RESTRICTION AND ELECTION  
REQUIREMENTS**

Commissioner for Patents  
Arlington, VA 22202

**RECEIVED**

**JAN 28 2003**

Sir:

**TECH CENTER 1800-23-1**

The Examiner is respectfully requested to enter the following amendments. A response to the Sequence Election Requirement mailed December 17, 2002 ("the Requirement" Paper No. 12) is also included herewith and the Examiner is respectfully requested to consider the remarks therein. The response is timely filed. Applicants believe no fee in addition to the fee for the extension of time is due in connection with this response. However, the Commissioner is authorized to charge any underpayment or credit any overpayment to Deposit Account No. 50-0892.

**AMENDMENT**

**In the claims:**

Please amend Claims 1 and 7 as follows:

1 (amended). A genetically engineered mammalian cell that has been mutated by a process comprising the insertion of a recombinantly manipulated polynucleotide sequence into a gene in said genetically engineered mammalian cell wherein said gene is identifiable as corresponding to SEQ ID NO: 393.

